fashion -WSS

fashion

author：leisure time 2025-10-02 22:57:18 - browse：571

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： NYU radiologists take on the challenge of expensive MRI machines

WSS

Hospitals look to new technology to keep health care workers safe

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Blood tests recalled over risk of missed heart attack diagnosis

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Mike Pence clashes with Tucker Carlson in Iowa

Eli Lilly to acquire Versanis in heated race for weight loss drugs

hotspot

fashion

knowledge

The high cost of giving birth even with insurance

Grail faces three suits alleging harassment, retaliation

What does generative AI mean for health care? We asked experts

Surge of respiratory disease in China has likely explanation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress must reauthorize a committee to support older Americans

Novavax promises a turnaround & Lilly roils the obesity market

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Hollywood unions extend contract negotiations for actors

Care demand spikes challenge UnitedHealth’s provider arm

explore

Mike Pence clashes with Tucker Carlson in Iowa

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Gain of function research would be limited under House proposal

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

hotspot

leisure time

focus

focus